



LEI: 549300Q7EXQQH6KF7Z84

14 January 2025

RTW Biotech Opportunities Ltd

Additional Investment in Numab Therapeutics

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note an additional investment in the Series C extension of **Numab Therapeutics** ("Numab"), a Swiss clinical stage biotech advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology.

Numab announced the completion of its CHF 50 million (~US 55m) Series C extension, in which the Company participated alongside other investment vehicles managed by RTW Investments, LP (the **Investment Manager**). The extension brought total Series C funding to CHF 180 million (~US 196m). The funds will be used to support the advancement of multiple potentially first-in-class and best-in-class programs into clinical development. The Company first invested in Numab's original Series C round in May of 2021.

Roderick Wong, Managing Partner and CIO at the Investment Manager said, "We are delighted to continue supporting Numab Therapeutics. Their innovative approach to developing multi-specific antibodies is particularly promising, and we believe that their groundbreaking research and development efforts hold great potential for transforming autoimmune and cancer treatments. Following J&J's announcement last summer to acquire Numab subsidiary, Yellow Jersey Therapeutics, we are optimistic that our continued partnership and this latest financing round will contribute to other significant advancements in immunology and oncology therapeutics."

The full text of the announcement can be accessed at <https://www.numab.com>.

For Further Information

RTW Investments, LP

+44 20 7959 6361

Woody Stileman, Managing Director, Business Development

biotechopportunities@rtwfunds.com

Krishna McCune, Director, Investor Relations

Cadarn Capital (PR & Communications/Distribution & IR Partner)

+44 79 8418 4461

Lucy Clark (PR)

Lucy@cadarncapital.com

David Harris (Distribution)

+44 73 6888 3211

david@cadarncapital.com

Deutsche Numis (Joint Corporate Broker)

+44 20 7260 1000

Freddie Barnfield

Nathan Brown

Euan Brown

BofA Securities (Joint Corporate Broker)

+44 20 7628 1000

Edward Peel

Alex Penney

Elysium Fund Management Limited

+44 14 8170 3100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

Morgan Stanley Fund Services USA LLC

+1 914 225 8885

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCEAPDFFNSEFA